X4 Pharmaceuticals, Inc. Stock
Price
Target price
-
-
-
-
-
?9.96
WKN: A2PFVY / Symbol: XFOR / Name: X4 Pharmaceuticals / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
X4 Pharmaceuticals, Inc. Stock
Our community is currently high on X4 Pharmaceuticals, Inc. with 5 Buy predictions and 1 Sell predictions.
Based on the current price of 0.17 € the target price of 9 € shows a potential of 5273.13% for X4 Pharmaceuticals, Inc. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for X4 Pharmaceuticals, Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of X4 Pharmaceuticals, Inc. in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of X4 Pharmaceuticals, Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| X4 Pharmaceuticals, Inc. | - | - | - | - | - | - | - |
| Evolus Inc | -2.840% | 7.594% | -16.281% | -34.825% | -4.330% | -23.883% | -40.750% |
| Rhythm Pharmaceuticals | -1.600% | -3.261% | -7.772% | 22.759% | -4.813% | 470.513% | 463.291% |
| Genfit S.A. | 0.890% | 0.296% | 33.531% | 277.790% | 151.673% | 287.966% | 320.236% |
Comments
X4 Pharmaceuticals (XFOR) was upgraded by Wells Fargo & Company to "strong-buy".
Show more
Ratings data for XFOR provided by MarketBeat
X4 Pharmaceuticals (XFOR) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $11.00 price target on the stock.
Show more
Ratings data for XFOR provided by MarketBeat
X4 Pharmaceuticals (XFOR) is now covered by Leerink Partners. They set an "outperform" rating and a $12.00 price target on the stock.
Show more
Ratings data for XFOR provided by MarketBeat
